BIOGEN INC (BIIB) Stock Fundamental Analysis
NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock - Currency: USD
Taking everything into account, BIIB scores 5 out of 10 in our fundamental rating. BIIB was compared to 572 industry peers in the Biotechnology industry. BIIB scores excellent on profitability, but there are some minor concerns on its financial health. BIIB is valued quite cheap, but it does not seem to be growing. These ratings could make BIIB a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year BIIB was profitable.
BIIB had a positive operating cash flow in the past year.
Each year in the past 5 years BIIB has been profitable.
Each year in the past 5 years BIIB had a positive operating cash flow.
1.2 Ratios
BIIB has a better Return On Assets (5.82%) than 95.38% of its industry peers.
BIIB's Return On Equity of 9.76% is amongst the best of the industry. BIIB outperforms 95.56% of its industry peers.
BIIB has a Return On Invested Capital of 9.92%. This is amongst the best in the industry. BIIB outperforms 95.91% of its industry peers.
BIIB had an Average Return On Invested Capital over the past 3 years of 10.57%. This is below the industry average of 14.04%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.82% | ||
| ROE | 9.76% | ||
| ROIC | 9.92% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
BIIB has a Profit Margin of 16.87%. This is amongst the best in the industry. BIIB outperforms 96.63% of its industry peers.
BIIB's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 26.35%, BIIB belongs to the best of the industry, outperforming 97.16% of the companies in the same industry.
BIIB's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 76.12%, BIIB belongs to the best of the industry, outperforming 85.44% of the companies in the same industry.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.35% | ||
| PM (TTM) | 16.87% | ||
| GM | 76.12% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
BIIB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
BIIB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BIIB has been reduced compared to 5 years ago.
Compared to 1 year ago, BIIB has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.75 indicates that BIIB is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.75, BIIB is doing good in the industry, outperforming 73.18% of the companies in the same industry.
The Debt to FCF ratio of BIIB is 2.50, which is a good value as it means it would take BIIB, 2.50 years of fcf income to pay off all of its debts.
BIIB's Debt to FCF ratio of 2.50 is amongst the best of the industry. BIIB outperforms 94.67% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that BIIB is not too dependend on debt financing.
BIIB has a Debt to Equity ratio of 0.27. This is in the lower half of the industry: BIIB underperforms 71.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 2.5 | ||
| Altman-Z | 2.75 |
ROIC/WACC1.1
WACC9%
2.3 Liquidity
A Current Ratio of 1.35 indicates that BIIB should not have too much problems paying its short term obligations.
BIIB's Current ratio of 1.35 is on the low side compared to the rest of the industry. BIIB is outperformed by 83.66% of its industry peers.
A Quick Ratio of 0.90 indicates that BIIB may have some problems paying its short term obligations.
With a Quick ratio value of 0.90, BIIB is not doing good in the industry: 88.45% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.9 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 9.22% over the past year.
BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
Looking at the last year, BIIB shows a decrease in Revenue. The Revenue has decreased by -1.62% in the last year.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)9.22%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%4.24%
Revenue 1Y (TTM)-1.62%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.87%
3.2 Future
BIIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.73% yearly.
BIIB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.31% yearly.
EPS Next Y-1.84%
EPS Next 2Y-1.03%
EPS Next 3Y1.97%
EPS Next 5Y3.73%
Revenue Next Year-4.47%
Revenue Next 2Y-2.57%
Revenue Next 3Y-0.84%
Revenue Next 5Y1.31%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.54 indicates a reasonable valuation of BIIB.
BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.87% of the companies in the same industry.
When comparing the Price/Earnings ratio of BIIB to the average of the S&P500 Index (29.63), we can say BIIB is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 8.70, the valuation of BIIB can be described as reasonable.
BIIB's Price/Forward Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.87% of the companies in the same industry.
BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.68.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.54 | ||
| Fwd PE | 8.7 |
4.2 Price Multiples
BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BIIB is cheaper than 99.11% of the companies in the same industry.
BIIB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIIB is cheaper than 98.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.15 | ||
| EV/EBITDA | 7.41 |
4.3 Compensation for Growth
BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.03%
EPS Next 3Y1.97%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
140.64
+3.56 (+2.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.24%
Inst Owner Change2.58%
Ins Owners0.12%
Ins Owner Change2.68%
Market Cap20.49B
Analysts74.76
Price Target202.08 (43.69%)
Short Float %2.58%
Short Ratio2.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.08%
Min EPS beat(2)0.67%
Max EPS beat(2)5.5%
EPS beat(4)4
Avg EPS beat(4)9.77%
Min EPS beat(4)0.67%
Max EPS beat(4)28.61%
EPS beat(8)8
Avg EPS beat(8)6.83%
EPS beat(12)11
Avg EPS beat(12)8.87%
EPS beat(16)14
Avg EPS beat(16)9.1%
Revenue beat(2)1
Avg Revenue beat(2)-0.29%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)0.11%
Revenue beat(4)2
Avg Revenue beat(4)-0.49%
Min Revenue beat(4)-2.86%
Max Revenue beat(4)1.48%
Revenue beat(8)5
Avg Revenue beat(8)0.17%
Revenue beat(12)7
Avg Revenue beat(12)0.42%
Revenue beat(16)10
Avg Revenue beat(16)0.84%
PT rev (1m)-4.4%
PT rev (3m)-13.2%
EPS NQ rev (1m)-1.78%
EPS NQ rev (3m)-2.24%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-0.37%
Revenue NQ rev (1m)-0.33%
Revenue NQ rev (3m)-0.16%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.54 | ||
| Fwd PE | 8.7 | ||
| P/S | 2.12 | ||
| P/FCF | 8.15 | ||
| P/OCF | 7.13 | ||
| P/B | 1.23 | ||
| P/tB | 37.54 | ||
| EV/EBITDA | 7.41 |
EPS(TTM)16.47
EY11.71%
EPS(NY)16.17
Fwd EY11.5%
FCF(TTM)17.26
FCFY12.28%
OCF(TTM)19.73
OCFY14.03%
SpS66.4
BVpS114.71
TBVpS3.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.82% | ||
| ROE | 9.76% | ||
| ROCE | 11.32% | ||
| ROIC | 9.92% | ||
| ROICexc | 11.09% | ||
| ROICexgc | 56.18% | ||
| OM | 26.35% | ||
| PM (TTM) | 16.87% | ||
| GM | 76.12% | ||
| FCFM | 26% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexcg growth 3Y14.15%
ROICexcg growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 2.5 | ||
| Debt/EBITDA | 1.41 | ||
| Cap/Depr | 53.45% | ||
| Cap/Sales | 3.72% | ||
| Interest Coverage | 10.39 | ||
| Cash Conversion | 89.23% | ||
| Profit Quality | 154.13% | ||
| Current Ratio | 1.35 | ||
| Quick Ratio | 0.9 | ||
| Altman-Z | 2.75 |
F-Score6
WACC9%
ROIC/WACC1.1
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)9.22%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%4.24%
EPS Next Y-1.84%
EPS Next 2Y-1.03%
EPS Next 3Y1.97%
EPS Next 5Y3.73%
Revenue 1Y (TTM)-1.62%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.87%
Revenue Next Year-4.47%
Revenue Next 2Y-2.57%
Revenue Next 3Y-0.84%
Revenue Next 5Y1.31%
EBIT growth 1Y24.37%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year19.92%
EBIT Next 3Y18.74%
EBIT Next 5Y0.74%
FCF growth 1Y103.57%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y85.85%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%